GUFICBIO.NSライブシグナル | Getagraph.comで利益を最大化

Live Chart Being Loaded With Signals

Commentary (8 5月 2024 @ 19:00):

Gufic Biosciences Limited engages in manufacture and marketing of active pharmaceutical ingredients (APIs), generic pharmaceuticals, and related services in India...

Stats
本日の出来高	24 700.00
平均出来高	108 519
時価総額	31.68B
EPS	INR0 ( 2024-02-13 )
次の収益日	( INR0 ) 2024-05-27
Last Dividend	INR0.100 ( 2023-09-21 )
Next Dividend	INR0 ( N/A )
P/E	36.60
ATR14	INR0.408 (0.13%)

ボリューム相関

長: -0.03 (neutral)

短: 0.62 (weak)

Signal:(66.558) Neutral

Gufic Biosciences Limited 相関

10 最も正の相関
FCONSUMER.NS	0.905
SHK.NS	0.899
PRAENG.NS	0.898
SUVEN.NS	0.897
PILITA.NS	0.896
SYNCOMF.NS	0.895
BAYERCROP.NS	0.893
RAMANEWS.NS	0.892
FSC.NS	0.891
AAREYDRUGS.NS	0.89

10 最も負の相関
SOMATEX.NS	-0.913
BSELINFRA.NS	-0.903
TARMAT.NS	-0.885
ABB.NS	-0.882
THERMAX.NS	-0.861
PGHL.NS	-0.858
FOSECOIND.NS	-0.846
KAYNES.NS	-0.845
MANINDS.NS	-0.845
SONATSOFTW.NS	-0.844

知っていましたか？

相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関（1つの変数が増加すると、もう一方は減少する）、1は完全な正の相関（1つの変数が増加すると、もう一方も増加する）、0は相関がないことを示します（変数間に関係がない）。

相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。

Gufic Biosciences Limited 相関 - 通貨/商品

0.07
( neutral )

-0.11
( neutral )

0.57
( weak )

-0.07
( neutral )

-0.76
( moderate negative )

0.65
( weak )

Gufic Biosciences Limited 財務諸表

Annual	2022
収益:	INR6.91B
総利益:	INR3.59B (51.95 %)
EPS:	INR8.22

FY	2022
収益:	INR6.91B
総利益:	INR3.59B (51.95 %)
EPS:	INR8.22

FY	2022
収益:	INR7.79B
総利益:	INR3.50B (44.86 %)
EPS:	INR9.89

FY	2021
収益:	INR4.88B
総利益:	INR2.30B (47.15 %)
EPS:	INR4.56

Financial Reports:

No articles found.

Gufic Biosciences Limited Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
INR0.200 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0.100 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)

Gufic Biosciences Limited Dividend Information - Dividend Junior

Dividend Sustainability Score: 4.52 - low (50.05%) | Divividend Growth Potential Score: 3.50 - Decrease likely (30.07%)

Very Unsafe

High risk of being cut

Unsafe

Heightened risk of being cut

Borderline

Moderate risk of being cut

Safe

Unlikely to be cut

Very Safe

Very unlikely to be cut

Information

First Dividend	INR0.220	2005-09-22
Last Dividend	INR0.100	2023-09-21
Next Dividend	INR0	N/A
Payout Date	0000-00-00
Next Payout Date	N/A
# dividends	21	--
Total Paid Out	INR1.530	--
Avg. Dividend % Per Year	0.04%	--
Score	1.93	--
Div. Sustainability Score	4.52
Div.Growth Potential Score	3.50
Div. Directional Score	4.01	--

Next Divdend (Est)
(2024-07-01)

INR0.108 Estimate 3.12 %

Dividend Stability

0.25 Very Poor

Dividend Score

1.93

Pay Frequency

Annually

Yearly Payout

Year	Amount	Yield
2005	INR0	0.00%
2006	INR0	0.00%
2007	INR0	0.00%
2008	INR0	0.00%
2009	INR0	0.00%
2010	INR0	0.00%
2011	INR0	0.00%
2012	INR0	0.00%
2013	INR0	0.00%
2014	INR0	0.00%
2015	INR0	0.00%
2016	INR0	0.00%
2017	INR0	0.00%
2018	INR0.0500	0.04%
2019	INR0.0500	0.05%
2020	INR0.0500	0.08%
2021	INR0.100	0.08%
2022	INR0.200	0.08%
2023	INR0.100	0.04%
2024	INR0	0.00%

Dividend Commentary

The company's low Dividend Sustainability Score (DSS) highlights potential challenges in upholding its current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In conclusion, a more vigilant stance is recommended given the company's tentative dividend landscape.

Top 10 dividend Companies for NSE

Symbol	Title	Last dividend	Frequency	Years Dividend	Yearly Dividend
ROHLTD.NS	Dividend Junior	2023-09-15	Sporadic	19	0.20%
LAURUSLABS.NS	Dividend Knight	2023-05-10	Semi-Annually	8	0.35%
FOSECOIND.NS	Dividend Knight	2023-05-17	Annually	22	0.68%
APOLLO.NS	Dividend Junior	2023-09-22	Annually	7	0.79%
TCI.NS	Dividend Junior	2023-07-25	Semi-Annually	23	0.70%
OBEROIRLTY.NS	Dividend Junior	2023-06-21	Sporadic	14	0.19%
INFOBEAN.NS	Dividend Junior	2023-07-21	Annually	7	0.37%
CONCOR.NS	Dividend Knight	2023-09-18	Semi-Annually	23	0.89%
SCI.NS	Dividend Junior	2023-09-01	Sporadic	22	0.25%
MALLCOM.NS	Dividend Junior	2023-09-04	Annually	3	0.20%

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	0.107	1.500	7.85	10.00	[0 - 0.5]
returnOnAssetsTTM	0	1.200	0	0	[0 - 0.3]
returnOnEquityTTM	0.228	1.500	8.58	10.00	[0.1 - 1]
payoutRatioTTM	0	-1.000	0	0	[0 - 1]
currentRatioTTM	0	0.800	-5.00	-4.00	[1 - 3]
quickRatioTTM	0	0.800	-4.71	-3.76	[0.8 - 2.5]
cashRatioTTM	0	1.500	-1.111	-1.667	[0.2 - 2]
debtRatioTTM	0	-1.500	0	0	[0 - 0.6]
interestCoverageTTM	8.29	1.000	8.04	8.04	[3 - 30]
operatingCashFlowPerShareTTM	3.71	2.00	8.76	10.00	[0 - 30]
freeCashFlowPerShareTTM	3.71	2.00	8.15	10.00	[0 - 20]
debtEquityRatioTTM	0	-1.500	0	0	[0 - 2.5]
grossProfitMarginTTM	0.467	1.000	5.56	5.56	[0.2 - 0.8]
operatingProfitMarginTTM	0.161	1.000	8.78	8.78	[0.1 - 0.6]
cashFlowToDebtRatioTTM	0	1.000	-1.111	-1.111	[0.2 - 2]
assetTurnoverTTM	0	0.800	-3.33	-2.67	[0.5 - 2]
Total Score				4.52

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	37.83	1.000	6.28	0	[1 - 100]
returnOnEquityTTM	0.228	2.50	9.09	10.00	[0.1 - 1.5]
freeCashFlowPerShareTTM	3.71	2.00	8.76	10.00	[0 - 30]
dividendYielPercentageTTM	0.0315	1.500	9.21	0	[0 - 0.4]
operatingCashFlowPerShareTTM	3.71	2.00	8.76	10.00	[0 - 30]
payoutRatioTTM	0	1.500	0	0	[0 - 1]
pegRatioTTM	-2.24	1.500	-10.00	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	0.0474	1.000	-1.315	0	[0.1 - 0.5]
Total Score				3.50

Gufic Biosciences Limited

Gufic Biosciences Limited engages in manufacture and marketing of active pharmaceutical ingredients (APIs), generic pharmaceuticals, and related services in India. It manufactures APIs and bulk drugs, such as antifungals, anesthetics, immuno suppressants, and intermediates for antifungals. The company also manufactures lyophilized injections, which include antibiotic, antifungal, cardiac, infertility, antiviral, and proton-pump inhibitor segments. In addition, it offers spark, criti care, and ferticare pharmaceutical products; and herbal and personal care products. The company supplies its products to hospital chains and medical facilities. It also exports its products to more than 20 countries. The company was founded in 1970 and is based in Mumbai, India.